Destara

RSS

ibandronic acid

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Destara has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 31/12/2009

Authorisation details

Product details
Name
Destara
Agency product number
EMEA/H/C/000103
Active substance
ibandronic acid
International non-proprietary name (INN) or common name
ibandronic acid
Therapeutic area (MeSH)
  • Hypercalcemia
  • Cancer
Anatomical therapeutic chemical (ATC) code
M05BA06
Publication details
Marketing-authorisation holder
Roche Registration Ltd.
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
25/06/1996
Contact address
Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom

Product information

31/12/2009 Destara - EMEA/H/C/000103 -

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

Treatment of tumour-induced hypercalcaemia with or without metastases.

How useful was this page?

Add your rating